Sign in

GLSI on Nasdaq

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is an American pharmaceutical preparations company based in Stafford.1 Its shares trade on Nasdaq under the symbol GLSI.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerGLSI on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersStafford, Texas1
  • Incorporated inDE2
  • Business address3992 Bluebonnet Dr, Building 14, Stafford, Tx 774772
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

The HER2/ neu protein is one of the most widely expressed tumor antigens in multiple malignances.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$19.4M in 2025+468% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$3.4M-$3.4M20192020: -$1.9M-$1.9M2020−46%2021: -$4.6M-$4.6M2021+147%2022: -$8.0M-$8.0M2022+75%2023: -$9.3M-$9.3M2023+16%2024: -$17.6M-$17.6M2024+89%2025: -$19.4M-$19.4M2025+10%
Net income456789-$19.4M in 2025+465% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$3.4M-$3.4M20192020: -$1.9M-$1.9M2020−46%2021: -$4.6M-$4.6M2021+145%2022: -$7.8M-$7.8M2022+71%2023: -$8.9M-$8.9M2023+14%2024: -$17.4M-$17.4M2024+96%2025: -$19.4M-$19.4M2025+11%

Every line of the income statement as filed: the last 2 fiscal years (annual) or 3 quarters (quarterly), latest first.9

Period ending2025-12-312024-12-31
Research and development$17.2M$15.5M
General and administrative$2.2M$2.2M
Total operating expenses$19.4M$17.6M
Loss from operations-$19.4M-$17.6M
Interest income$89.7K$223.0K
Net loss-$19.4M-$17.4M
Net loss per common share, basic-$1.43-$1.34
Net loss per common share, diluted-$1.43-$1.34
Weighted average common shares outstanding, basic13.5M shares13.0M shares
Weighted average common shares outstanding, diluted13.5M shares13.0M shares

Compare Greenwich LifeSciences, Inc. with another company

Corporate structure

Greenwich LifeSciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Greenwich LifeSciences, Inc.

  • Michael Guy Weiner Filed SC 13G on Greenwich LifeSciences, Inc., latest Jun 22, 2022
  • Greenwich LifeSciences, Inc. Stafford, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Greenwich LifeSciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.2M9 Dec 31, 2025$4.1M9 Dec 31, 2024+51.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, net$1.8K9 Dec 31, 2024$5.4K8 Dec 31, 2023−67.0%

Properties, in its own words

We sublease a facility to support our clinical trial operations and research and development.

Item 2 of the 10-K filed Jun 1, 2026.3

Leadership

Who has led Greenwich LifeSciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Snehal Patel2020–now

Chief financial officer

  1. Snehal Patel2020–now
2025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Medical OfficerF. Joseph Daugherty named Jun 18, 202418

Timeline

  1. Dec 18, 20258-K Shareholder vote19
  2. Jul 24, 20258-K Change of auditor20
  3. Dec 19, 20248-K Shareholder vote21
  4. Jun 17, 20248-K Entered a material agreement; Unregistered sale of shares22
  5. Feb 20, 20248-K Change of auditor23
  6. Feb 14, 20248-K Other events24
  7. Dec 15, 20238-K Shareholder vote25
  8. Apr 13, 20238-K Other events26
  9. Mar 13, 20238-K Other events27
  10. Dec 9, 20228-K Shareholder vote28
  11. Jul 12, 20228-K Other events29
  12. Jul 12, 20228-K Entered a material agreement30
  13. Sep 24, 2020New chief executive Snehal Patel becomes CEO12

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.30) a share, on Nov 14, 2025.31

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

191 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 16 major events, 119 insider forms, 1 large holders, 1 private raises, 33 other. The latest 20:

  1. Aug 11, 202610-Q EDGAR
  2. Jul 30, 20264 EDGAR
  3. Jul 29, 20264 EDGAR
  4. Jul 27, 20264 EDGAR
  5. Jun 4, 202610-Q EDGAR
  6. Jun 1, 202610-K EDGAR
  7. Mar 31, 2026NT 10-K EDGAR
  8. Jan 15, 20264 EDGAR
  9. Jan 14, 20264 EDGAR
  10. Jan 5, 20264 EDGAR
  11. Jan 2, 20264 EDGAR
  12. Dec 19, 20254 EDGAR
  13. Dec 18, 20258-K EDGAR
  14. Nov 28, 20254 EDGAR
  15. Nov 17, 20254 EDGAR
  16. Nov 14, 202510-Q EDGAR
  17. Nov 12, 20254 EDGAR
  18. Nov 4, 20254 EDGAR
  19. Nov 3, 2025ARS EDGAR
  20. Nov 3, 2025DEFA14A EDGAR

The 191 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

108 open-market trades by officers, directors and large owners since October 2021: 108 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 29, 2026Patel SnehalCEO and CFOBuy700$13.10$9.2KForm 4
Jul 28, 2026Patel SnehalCEO and CFOBuy1,500$13.59$20.4KForm 4
Jul 27, 2026Patel SnehalCEO and CFOBuy1,500$13.62$20.4KForm 4
Jul 24, 2026Patel SnehalCEO and CFOBuy1,100$12.88$14.2KForm 4
Jul 23, 2026Patel SnehalCEO and CFOBuy2,500$13.14$32.9KForm 4
Jan 13, 2026Patel SnehalCEO and CFOBuy1,800$29.83$53.7KForm 4
Jan 12, 2026Patel SnehalCEO and CFOBuy2,900$27.54$79.9KForm 4
Dec 31, 2025Patel SnehalCEO and CFOBuy4,300$21.36$91.8KForm 4
Dec 30, 2025Patel SnehalCEO and CFOBuy2,900$21.73$63.0KForm 4
Dec 18, 2025Patel SnehalCEO and CFOBuy4,100$12.62$51.7KForm 4
Nov 25, 2025Patel SnehalCEO and CFOBuy4,600$8.37$38.5KForm 4
Nov 7, 2025Patel SnehalCEO and CFOBuy10,600$8.43$89.4KForm 4
Oct 31, 2025Patel SnehalCEO and CFOBuy2,300$9.26$21.3KForm 4
Apr 25, 2025Patel SnehalCEO and CFOBuy3,600$9.88$35.6KForm 4
Apr 17, 2025Patel SnehalCEO and CFOBuy5,400$8.98$48.5KForm 4
Apr 7, 2025Patel SnehalCEO and CFOBuy3,600$9.10$32.8KForm 4
Apr 4, 2025Patel SnehalCEO and CFOBuy5,500$8.73$48.0KForm 4
Jan 10, 2025Patel SnehalCEO and CFOBuy2,500$12.51$31.3KForm 4
Jan 7, 2025Patel SnehalCEO and CFOBuy1,800$13.75$24.8KForm 4
Jan 6, 2025Patel SnehalCEO and CFOBuy1,100$13.31$14.6KForm 4

All 108 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Michael Guy WeinerSC 13G, 1 filing Jun 22, 202232

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Snehal PatelChief Executive Officer61$612.6K$6.2M33
2023Snehal PatelChief Executive Officer61$556.9K$2.8M33

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$2.5M 2024–2024
Money received by yearMoney received by year, 2024–2024: $2.5M in all. Private raises (Form D) $2.5M.$0$1M$2M$3M2024 · Private raises (Form D): $2.5M2024
Figures by year
YearPrivate raises (Form D)Total
2024$2.5M$2.5M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jun 13, 2024Raised $2.5 million in a private offering of equity18 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 58. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.485,854$11.4M0.0%+51,994
Vanguard Capital Management LLC278,190$6.5M0.0%−20,076
Geode Capital Management, LLC168,179$3.9M0.0%+12,713
State Street Corp143,086$3.4M0.0%+9,211
Vanguard Portfolio Management LLC80,861$1.9M0.0%+21,950
Northern Trust Corp80,228$1.9M0.0%+5,103
Bank of New York Mellon Corp47,900$1.1M0.0%+1,377
Vanguard Fiduciary Trust Co45,965$1.1M0.0%+1,057
Morgan Stanley43,447$1.0M0.0%+13,620
Goldman Sachs Group Inc39,329$922.7K0.0%−192
Russell Investments Group, Ltd.34,353$805.9K0.0%−5,344
Jane Street Group, LLC27,694$649.7K0.0%New
UBS Group AG23,409$549.2K0.0%+2,293
State Of Wisconsin Investment Board22,639$531.1K0.0%+2,300
Massachusetts Financial Services Co /ma/17,922$420.4K0.0%New
Strs Ohio17,800$417.6K0.0%+4,100
Charles Schwab Investment Management Inc17,098$401.1K0.0%+495
Vanguard Global Advisers, LLC11,871$278.5K0.0%+1,536
Ancora Advisors LLC10,740$252.0K0.0%−26,760
Stifel Financial Corp10,023$235.1K0.0%New
Raymond James Financial Inc9,137$214.4K0.0%−700
Rhumbline Advisers8,387$196.8K0.0%+341
Wells Fargo & Company/mn6,144$144.1K0.0%+3,704
Deutsche Bank Ag\5,351$125.5K0.0%+189
Fmr LLC3,996$93.7K0.0%−111

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Greenwich LifeSciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGreenwich LifeSciences, Inc.1
  • CIK0001799788
  • Employer ID (EIN)20-54737093
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3992 Bluebonnet Dr, Building 14, Stafford, TX 774771
  • Phone203-434-32901
  • Shares outstanding14,678,208 as of Jul 24, 202611
  • Public float$56.0M as of Jun 30, 20253
  • AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJan 27, 20201
  • Filings276 in all: 4 (135), 8-K (31), 10-Q (18), 3 (9), CORRESP (9), UPLOAD (7), 10-K (6), NT 10-Q (6)1
    All 34 form types

    DEF 14A (5), DEFA14A (5), EFFECT (4), S-1/A (4), 424B4 (3), ARS (3), FWP (3), NT 10-K (3), 424B3 (2), DRS (2), DRSLTR (2), S-1 (2), S-3 (2), S-8 (2), SC 13D (2), 10-K/A (1), 3/A (1), 4/A (1), 424B5 (1), 8-A12B (1), CERT (1), D (1), DRS/A (1), S-1MEF (1), S-3/A (1), SC 13G (1)

  • Latest filingsAnnual report (10-K) Jun 1, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Nov 3, 2025
    Latest 8-K (8-K) Dec 18, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par valueGLSINASDAQ

From the cover page of the 10-K filed Jun 1, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Greenwich LifeSciences, Inc. names in Item 1A of its 10-K filed Jun 1, 2026: 72 risks under these headings, as written.3

  • Risks Relating to Our Financial Position and Capital Needs
  • We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.
  • We need significant additional financing to fund our operations and complete the development and, if approved, the commercialization of our product candidate. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  • We may consider strategic alternatives in order to maximize stockholder value, including financings, strategic alliances, acquisitions or the possible sale of the Company. We may not be able to identify or consummate any suitable strategic alternatives.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidate on unfavorable terms to us.
  • We currently have no source of revenues. We may never generate revenues or achieve profitability.
  • The Tax Cuts and Jobs Act could adversely affect our business and financial condition.
  • Our ability to use net operating losses to offset future taxable income may be subject to limitations.
  • Risks Related to the Development and Regulatory Approval of Our Product Candidate
  • Clinical-stage biopharmaceutical companies with product candidates in clinical development face a wide range of challenging activities which may entail substantial risk.
  • We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidate is being studied which could delay or prevent the start of clinical trials for our product candidate.
  • The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our existing product candidate in clinical trials, and any other product candidates that may advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval.
The other 62 risks
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, including the risk of a clinical trial being placed on clinical hold.
  • Data from our clinical trials that we announce or publish from time to time may change as more patient data become available either through long-term patient follow-up and/or as such data is audited and verified, which could result in material changes to clinical and safety profiles for our products.
  • In the clinical trials using GP2, improper intradermal injections or poor HLA binding by GP2 may potentially jeopardize the outcome of the trials.
  • Risks associated with out-licensing GP2 or future product candidates in foreign countries could materially adversely affect the commercialization of our products.
  • Risks associated with operating in foreign countries could materially adversely affect our product development.
  • Our current and future product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval.
  • Our product development program may not uncover all possible adverse events that patients who take our product candidate may experience. The number of patients exposed to our product candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is administered to more patients and for greater periods of time.
  • Failure to successfully validate and develop a companion diagnostic for our product candidate could harm our drug development strategy and operational results.
  • Our future success is dependent on the regulatory approval of our product candidate.
  • Our current product candidate and future product candidates could fail to receive regulatory approval from the FDA.
  • Failure to obtain regulatory approval in international jurisdictions would prevent our product candidate from being marketed abroad.
  • Even if our current candidate receives regulatory approval, it may still face future development and regulatory difficulties.
  • Risks Related to Our Manufacturing
  • We have limited to no manufacturing, sales, marketing or distribution capability and must rely upon third parties for such.
  • We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidate.
  • In the clinical trials using GP2, GM-CSF is also administered and its availability is dependent upon a third-party manufacturer, which may or may not reliably provide GM-CSF, thus jeopardizing the completion of the trials.
  • If any of our CMOs’ clinical manufacturing facilities are damaged or destroyed or production at such facilities is otherwise interrupted, our business and prospects would be negatively affected.
  • Risks Related to Our Dependence on Third Parties and Our License Agreements
  • We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, or if we lose any of our CROs or other key third-party vendors, we may not be able to obtain regulatory approval for or commercialize our current or future product candidates on a timely basis, if at all.
  • We are dependent on technologies we license, and if we lose the right to license such technologies or we fail to license new technologies in the future, our ability to develop new products would be harmed, and if we fail to meet our obligations under our license agreements, we may lose the ability to develop our product candidate.
  • Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural disaster, pandemic, war or other catastrophic event.
  • We may not realize the benefits of our strategic alliances that we may form in the future.
  • Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business.
  • We may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize our product candidate.
  • Risks Related to Our Intellectual Property
  • We rely on an exclusive license granted to us by HJF with respect to GP2, and if HJF does not adequately defend such license, our business may be harmed.
  • It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidate, others could compete against us more directly, which would harm our business, possibly materially.
  • If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patents and other intellectual property rights.
  • We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidate.
  • If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets.
  • Our intellectual property may not be sufficient to protect our product candidate from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.
  • Risks Related to Commercialization of Our Current Product Candidate and Future Product Candidates
  • Our commercial success depends upon attaining significant market acceptance of our current product candidate and future product candidates, if approved, among physicians, patients, healthcare payors and cancer treatment centers.
  • Even if we are able to commercialize our current product candidate or any future product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the U.S. and in other countries in which we seek to commercialize our products, which could harm our business.
  • Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
  • Price controls may be imposed in foreign markets, which may adversely affect our future profitability.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidate, which could make it difficult for us to sell our product candidates, if licensed, profitably.
  • We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition.
  • Risks Related to Healthcare Compliance Regulations
  • Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. If we or they are unable to comply with these provisions, we may become subject to civil and criminal investigations and proceedings that could have a material adverse effect on our business, financial condition and prospects.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the U.S. and require us to develop and implement costly compliance programs.
  • Risks Related to our Business Operations
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • The COVID-19 coronavirus could adversely impact our business in the U.S. and in other countries, including several key activities, including clinical trial activities, manufacturing of drugs and clinical supplies, exportation of drug and supplies, and management of international payments and cash flow that are critical to our success.
  • Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.
  • Significant disruptions of information technology systems, computer system failures or breaches of information security could adversely affect our business.
  • We will need to grow the size of our organization in the future, and we may experience difficulties in managing this growth.
  • Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.
  • Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • We are periodically involved in various litigation and/or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition, and results of operations.
  • We may hold cash and cash equivalents at various foreign subsidiaries and in countries outside of the US that may not be readily available to meet cash requirements.
  • We may be adversely affected by the effects of inflation and a potential recession.
  • Risks Related to Owning our Common Stock
  • The price of our common stock may fluctuate substantially.
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.
  • Because certain of our stockholders control a significant number of shares of our common stock, they may have effective control over actions requiring stockholder approval.
  • Future sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
  • We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.
  • We may be at risk of securities class action litigation.
  • Our common stock is currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.
  • Our second amended and restated certificate of incorporation (“Amended and Restated Certificate of Incorporation”) and our second amended and restated bylaws (the “Amended and Restated Bylaws”) and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management is required to devote substantial time to compliance matters.
  • Our Amended and Restated Bylaws provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between the Company and its stockholders, which could limit stockholders’ ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.

Legal proceedings

We may be involved from time to time in ordinary litigation, negotiation, and settlement matters that will not have a material effect on our operations or finances. We are not currently party to any material legal proceedings, and we are not aware of any pending or threatened litigation against us.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
  33. 33